Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q99684
UPID:
GFI1_HUMAN
Alternative names:
Growth factor independent protein 1; Zinc finger protein 163
Alternative UPACC:
Q99684; Q8N564
Background:
Zinc finger protein Gfi-1, also known as Growth factor independent protein 1 and Zinc finger protein 163, plays a pivotal role in hematopoiesis. It acts as a transcription repressor, essential for the development of multiple blood cell lines. Gfi-1's ability to bind specific promoter regions and form complexes that suppress genes implicated in blood cell development underscores its significance in regulating neutrophil differentiation and lymphoid cell proliferation.
Therapeutic significance:
Gfi-1's involvement in severe congenital Neutropenia and chronic idiopathic Neutropenia of adults highlights its therapeutic potential. Understanding the role of Zinc finger protein Gfi-1 could open doors to potential therapeutic strategies for these hematopoietic disorders, offering hope for targeted treatments that could alleviate or even cure these conditions.